Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Expressing Solid Tumors”

63 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 63 results

Early research (Phase 1)Temporarily pausedNCT05076591
What this trial is testing

IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced Breast CancerAdvanced Gastric Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 135
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362
What this trial is testing

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Who this might be right for
Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more
BicycleTx Limited 329
Testing effectiveness (Phase 2)Looking for participantsNCT06015048
What this trial is testing

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Who this might be right for
HER2-expressing Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 364
Early research (Phase 1)Study completedNCT00207012
What this trial is testing

MAD Refractory: Solid Tumor QD w/o Break

Who this might be right for
HER2 or EGFR Expressing Advanced Solid Malignancies
Bristol-Myers Squibb 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT07122063
What this trial is testing

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd. 266
Early research (Phase 1)Ended earlyNCT05511844
What this trial is testing

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene Amplification+1 more
Orum Therapeutics USA, Inc. 25
Early research (Phase 1)Study completedNCT04319757
What this trial is testing

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Who this might be right for
Locally Advanced Solid TumorMetastatic CancerSolid Tumor+2 more
Acepodia Biotech, Inc. 12
Early research (Phase 1)Active Not RecruitingNCT03448042
What this trial is testing

Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Who this might be right for
Solid Tumors
Genentech, Inc. 123
Testing effectiveness (Phase 2)Study completedNCT00900627
What this trial is testing

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Cancer
AstraZeneca 330
Not applicableActive Not RecruitingNCT07387874
What this trial is testing

A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

Who this might be right for
Recurrent or Metastatic Solid Tumors
Lixiaoling 30
Testing effectiveness (Phase 2)Looking for participantsNCT06695845
What this trial is testing

Zanidatamab in Patients With HER2-expressing Tumors

Who this might be right for
Breast CancerGastric CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals 200
Testing effectiveness (Phase 2)Ended earlyNCT01569412
What this trial is testing

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

Who this might be right for
Her2/Neu Positive Advanced Solid Tumors
Krankenhaus Nordwest 14
Early research (Phase 1)Study completedNCT03383692
What this trial is testing

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Who this might be right for
Neoplasm Metastasis
Daiichi Sankyo Co., Ltd. 40
Early research (Phase 1)Looking for participantsNCT04585958
What this trial is testing

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Who this might be right for
Metastatic Malignant Solid NeoplasmPlatinum-Resistant Ovarian High Grade Serous AdenocarcinomaUnresectable Malignant Solid Neoplasm
National Cancer Institute (NCI) 55
Not applicableEnded earlyNCT02840110
What this trial is testing

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Who this might be right for
B Cell LymphomasMultiple MyelomaSolid Tumor+1 more
Cogent Biosciences, Inc. 22
Early research (Phase 1)Looking for participantsNCT06364410
What this trial is testing

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Looking for participantsNCT07228247
What this trial is testing

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

Who this might be right for
Solid Tumors, Adult
Hutchmed 147
Early research (Phase 1)Ended earlyNCT05013554
What this trial is testing

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

Who this might be right for
Neoplasm MalignantBreast CancerLung Neoplasm Malignant+2 more
Sanofi 44
Early research (Phase 1)Active Not RecruitingNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Next Page